Long-Term Use of Proton Pump Inhibitors and Risk of Gastric Cancer Development after Treatment for H. Pylori: A Population-Based Study

Cheung, Michael K.; Wong, Angel; Chen, Lijia; Chan, Esther Wai Yin; Wong, Ian C. K.; Leung, Wai Keung

doi:10.1016/s0016-5085(17)32875-5

Cited by 6 publications

(21 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Moreover, we calculated the pooled prevalence of GC among PPI users and non-users in five retrospective cohort studies. 17,[28][29][30][31] Finally, we assessed the risk of publication bias using Egger's test. 32…”

Section: Statistical Approachmentioning

confidence: 99%

“…Our final meta-analysis summarizes eight casecontrol [15][16][17]27,[33][34][35]37 and five retrospective cohort studies 17,[28][29][30][31] with an overall population of 1,662,881 individuals from Europe (Denmark, Sweden, United Kingdom), Canada, United States, and Asia (Hongkong, Japan, Taiwan).…”

Section: General Characteristics Of Included Studiesmentioning

confidence: 99%

“…Three studies 17,19,28 assessed GC risk in relation to the number of PPI prescriptions, three studies according to the number of defined daily doses (DDDs) 16,17,34 ; five studies reported the duration of PPI use, 14,16,17,29,31,33 among those one study with additional information on PPI frequency. 31 The five remaining studies did not provide detailed analyses either on PPI frequency, dosage, or duration. 15,27,30,34,37 In two studies, 14,28,29 there was no information on the proportion of cases and controls in unexposed individuals.…”

Section: General Characteristics Of Included Studiesmentioning

confidence: 99%

See 2 more Smart Citations

Association between proton-pump inhibitors and the risk of gastric cancer: a systematic review with meta-analysis

Segna

Brusselaers

Glaus

et al. 2021

Therap Adv Gastroenterol

View full text Add to dashboard Cite

Introduction: The use of proton-pump inhibitors (PPI) may be associated with an increased risk of gastric cancer (GC). Objective: To review and meta-analyse available literature investigating the association between PPI use and GC risk. Methods: Two independent reviewers systematically searched Ovid MEDLINE, EMBASE, and Cochrane Library (inception to July 2020) for case-control and cohort studies assessing the association between PPI use and GC according to a predefined protocol in PROSPERO (CRD42018102536). Reviewers independently assessed study quality, extracted data, and meta-analysed available and newly calculated odds ratios (ORs) using a random-effects model, and stratified for GC site (cardia versus non-cardia) and PPI duration (<1 year, 1–3 years, >3 years). Results: We screened 2,396 records and included five retrospective cohort and eight case-control studies comprising 1,662,881 individuals in our meta-analysis. In random-effect models, we found an increased GC risk in PPI users [OR: 1.94, 95% confidence interval (95% CI): 1.47–2.56] with high statistical heterogeneity ( I2 = 82%) and overall moderate risk of bias. Stratified analyses indicated a significant risk increase in non-cardia (OR: 2.20, 95% CI: 1.44–3.36, I2 = 77%) with a similar non-significant trend in cardia regions (OR: 1.77, 95% CI: 0.72–4.36, I2 = 66%). There was no GC increase with longer durations of PPI exposure (<1 year: OR: 2.29, 95% CI: 2.13–2.47, I2 = 0%; 1–3 years: OR: 1.46, 95% CI: 0.53–4.01, I2 = 35%; >3 years: OR: 2.08, 95% CI: 0.56–7.77, I2 = 61%). Conclusion: We found a twofold increased GC risk among PPI users, but this association does not confirm causation and studies are highly heterogeneous. PPI should only be prescribed when strictly indicated.

show abstract

Section: Statistical Approachmentioning

confidence: 99%

Section: General Characteristics Of Included Studiesmentioning

confidence: 99%

Section: General Characteristics Of Included Studiesmentioning

confidence: 99%

See 1 more Smart Citation

Association between proton-pump inhibitors and the risk of gastric cancer: a systematic review with meta-analysis

Segna

Brusselaers

Glaus

et al. 2021

Therap Adv Gastroenterol

View full text Add to dashboard Cite

show abstract

“…We identified subjects who had received a course of clarithromycin-containing triple therapy for H pylori infection between January 2003 and December 2012 in all public hospitals managed by the Hospital Authority in Hong Kong. 13 The Hospital Authority is the sole public health service provider, serving a local population of 7.3 million under a heavily subsidized public health care system. 14 It manages 87% of all hospital beds in Hong Kong and has more than 7.5 million outpatient specialist consultations per year.…”

Section: Study Design and Data Sourcementioning

confidence: 99%

Effects of Helicobacter pylori Treatment on Incidence of Gastric Cancer in Older Individuals

et al. 2018

Self Cite

View full text Add to dashboard Cite

show abstract

“…Os estudos epidemiológicos do tipo coorte descrevem a presença de eventos novos, como incidência dentro de uma população estudada durante um dado período de observação (MERCHÁN-HAMANN e TAUIL, 2021). Cheung et al, (2017) observaram uma incidência de 0,24% de câncer gástrico com o uso contínuo de IBPs por 7,6 anos. Nos estudos de Associação Do Uso Dos Inibidores De Bomba De Prótons Ao Câncer Gástrico Brusselaers et al, (2019), observou-se uma incidência relativamente maior de 0,36% e num intervalo de tempo inferior de uso contínuo de IBPs a partir de 5 anos.…”

Section: Metodologiaunclassified

Associação Do Uso Dos Inibidores De Bomba De Prótons Ao Câncer Gástrico

Finck¹,

Sugawara²

2021

Revista Científica Multidisciplinar Núcleo do Conhecimento

View full text Add to dashboard Cite

A associação dos inibidores de bomba de prótons (IBPs) ao câncer gástrico é uma informação facilmente encontrada na internet, na maioria das vezes em páginas sem caráter científico. Os IBPs são medicamentos amplamente utilizados nos distúrbios gastrointestinais, tendo o omeprazol como um dos seus representantes. Segundo o Instituto Nacional do Câncer – INCA, no Brasil, o câncer gástrico é o terceiro tipo de câncer mais frequente em homens e o quinto mais frequente em mulheres. O objetivo deste estudo é investigar à associação do uso de IBPs ao desenvolvimento de câncer gástrico. A metodologia consistiu em uma revisão integrativa da literatura seguindo a estratégia PICO na formulação da pergunta da pesquisa. O levantamento bibliográfico buscou artigos publicados que possuem como população-alvo indivíduos adultos, maiores de 18 anos, independente do sexo, que estiveram sob uso de IBPs, comparados com controles sem intervenção ou placebo, associados ao desenvolvimento do câncer gástrico. As bases de dados utilizadas foram PUBMED e BVS. Foram incluídos artigos em inglês e português, publicados entre 2017 a 2020. Esta pesquisa analisa que a relação entre os IBPs e o câncer gástrico ainda não está plenamente estabelecida. Nos casos em que se observou correlação positiva pode-se concluir, ao menos parcialmente, que o câncer gástrico é um evento de curto prazo, incluindo de menos de 1 ano de uso, suportando a ideia de que o câncer gástrico como um evento agudo.

show abstract

Long-Term Use of Proton Pump Inhibitors and Risk of Gastric Cancer Development after Treatment for H. Pylori: A Population-Based Study

Cited by 6 publications

References 0 publications

Association between proton-pump inhibitors and the risk of gastric cancer: a systematic review with meta-analysis

Association between proton-pump inhibitors and the risk of gastric cancer: a systematic review with meta-analysis

Effects of Helicobacter pylori Treatment on Incidence of Gastric Cancer in Older Individuals

Associação Do Uso Dos Inibidores De Bomba De Prótons Ao Câncer Gástrico

Contact Info

Product

Resources

About